The estimated Net Worth of Nilda Mesa is at least $3.31 Million dollars as of 13 July 2024. Ms. Mesa owns over 900 units of United Therapeutics Corp stock worth over $2,079,563 and over the last 6 years she sold UTHR stock worth over $815,917. In addition, she makes $419,405 as Independent Director at United Therapeutics Corp.
Nilda has made over 13 trades of the United Therapeutics Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 900 units of UTHR stock worth $311,571 on 13 July 2024.
The largest trade she's ever made was exercising 2,660 units of United Therapeutics Corp stock on 31 October 2019 worth over $920,865. On average, Nilda trades about 722 units every 95 days since 2018. As of 13 July 2024 she still owns at least 6,007 units of United Therapeutics Corp stock.
You can see the complete history of Ms. Mesa stock trades at the bottom of the page.
Nilda Mesa serves as Independent Director of the Company. Ms. Mesa has had a long and innovative career in environment, energy and sustainability at the city, state, national and global levels, and now writes and presents extensively on climate, energy, equity and urban systems relating to them. From 2014-2016, Ms. Mesa served as Director of the New York City Mayor's Office of Sustainability, where she led the pathbreaking OneNYC long-term sustainability plan for the city. As chief sustainability officer for New York City, she oversaw programs in climate, energy, sustainability, air quality and public health, waste, green buildings, transportation, public education and other initiatives. In 2016, she returned to Columbia University as an adjunct professor at the School of International and Public Affairs, as well as Director of the Urban Sustainability and Equity Planning Program with Columbia's Center for Sustainable Urban Development at the Earth Institute, positions she continues to hold today. In 2006, she founded Columbia's Office of Environmental Stewardship, one of the first in the United States for a university. She also served as Chief Administrative Officer at the Columbia Journalism School from 2012-2014. Before joining Columbia, Ms. Mesa served in environmental leadership roles at the White House Council on Environmental Quality, the U.S. Air Force, the U.S. Environmental Protection Agency, and the California Attorney General's office, and practiced law in both the public and private sectors. Her work has involved extensive international experience, including most recently a 2018 appointment as a visiting professor at the Paris Institute of Political Studies (Sciences Po), an international research university in France.
As the Independent Director of United Therapeutics Corp, the total compensation of Nilda Mesa at United Therapeutics Corp is $419,405. There are 15 executives at United Therapeutics Corp getting paid more, with Martine Rothblatt having the highest compensation of $15,627,500.
Nilda Mesa is 60, she's been the Independent Director of United Therapeutics Corp since 2018. There are 9 older and 11 younger executives at United Therapeutics Corp. The oldest executive at United Therapeutics Corp is Louis Sullivan, 86, who is the Independent Director.
Nilda's mailing address filed with the SEC is C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING, MD, 20910.
Over the last 20 years, insiders at United Therapeutics Corp have traded over $68,910,395 worth of United Therapeutics Corp stock and bought 229,703 units worth $13,655,671 . The most active insiders traders include Martine A Rothblatt, David Zaccardelli und Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of $2,310,818. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth $991,341.
united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
United Therapeutics Corp executives and other stock owners filed with the SEC include: